Loading...

Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 43.94 USD -0.27% Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one PFE stock under the Base Case scenario is 53.17 USD. Compared to the current market price of 43.94 USD, Pfizer Inc is Undervalued by 17%.

The Intrinsic Value is calculated as the average of the two valuation methods:

PFE Intrinsic Value
Base Case
53.17 USD
Undervaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

PFE Profitability Score
Profitability Due Diligence

Pfizer Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Negative Revenue Growth Forecast
Positive 3-Year Average ROIC
Exceptional 1-Year Revenue Growth
Positive ROIC
71/100
Profitability
Score

Pfizer Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

PFE Solvency Score
Solvency Due Diligence

Pfizer Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Liabilities
Long-Term Liabilities
Low D/E
75/100
Solvency
Score

Pfizer Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
66%
Gross Margin
38%
Operating Margin
31%
Net Margin
23%
FCF Margin
37%
ROE
23%
ROIC
Other

PFE Capital Structure
Pfizer Inc

Market Capitalization 247B USD
Total Debt 34.1B USD
Minority Interest 259M USD
Preferred Equity 0 USD
Cash and Equivalents 1.3B USD
Short-Term Investments 34.8B USD
Enterprise Value 245B USD

Wall St
Price Targets

PFE Price Targets Summary
Pfizer Inc

Wall Street analysts forecast PFE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PFE is 56.6 USD with a low forecast of 44.44 USD and a high forecast of 78.75 USD.

Lowest
Price Target
44.44 USD
1% Upside
Average
Price Target
56.6 USD
29% Upside
Highest
Price Target
78.75 USD
79% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

PFE Competitors
Pfizer Inc

PFE Suppliers & Customers
Pfizer Inc

Pfizer Inc has 167 key suppliers from 18 countries and 19 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
94
Veeva Systems Inc
Health Care
Omnicom Group Inc
Media
D
DoubleVerify Holdings Inc
Technology
Ampco-Pittsburgh Corp
Metals & Mining
Bristol-Myers Squibb Co
Pharmaceuticals
Abbvie Inc
Biotechnology
Model N Inc
Technology
Quotient Technology Inc
Retail
Smartsheet Inc
Technology
Corning Inc
Electrical Equipment
Biohaven Pharmaceutical Holding Company Ltd
Biotechnology
Box Inc
Technology
Alaska Air Group Inc
Airlines
Catalent Inc
Pharmaceuticals
Alexandria Real Estate Equities Inc
Real Estate
Bright Horizons Family Solutions Inc
Diversified Consumer Services
Merck & Co Inc
Pharmaceuticals
Flowserve Corp
Machinery
Zoetis Inc
Pharmaceuticals
Alteryx Inc
Technology
Informatica Inc
Technology
Gilead Sciences Inc
Biotechnology
Upland Software Inc
Technology
Ligand Pharmaceuticals Inc
Biotechnology
Oyster Point Pharma Inc
Biotechnology
Homology Medicines Inc
Biotechnology
Cardiff Oncology Inc
Biotechnology
Voyager Therapeutics Inc
Biotechnology
R
Royalty Pharma PLC
Pharmaceuticals
A
Axsome Therapeutics Inc
Pharmaceuticals
9
908 Devices Inc.
Electrical Equipment
Beam Therapeutics Inc
Biotechnology
Regenxbio Inc
Biotechnology
I
IDEAYA Biosciences Inc
Biotechnology
e
eFFECTOR Therapeutics Inc
Biotechnology
Coherus BioSciences Inc
Biotechnology
Halozyme Therapeutics Inc
Biotechnology
Arvinas Inc
Pharmaceuticals
Fuelcell Energy Inc
Electrical Equipment
Calithera Biosciences Inc
Biotechnology
Omeros Corp
Pharmaceuticals
Cerevel Therapeutics Holdings Inc
Biotechnology
P
Pyxis Oncology Inc
Biotechnology
Certara Inc
Health Care
ICU Medical Inc
Health Care
ANSYS Inc
Technology
Guardant Health Inc
Health Care
Maravai LifeSciences Holdings Inc
Life Sciences Tools & Services
Exelixis Inc
Biotechnology
C
Cyteir Therapeutics Inc
Biotechnology
Catalyst Biosciences Inc
Biotechnology
B
Biodesix Inc
Health Care
Mirati Therapeutics Inc
Biotechnology
Premier Inc
Health Care
CRA International Inc
Professional Services
G1 Therapeutics Inc
Biotechnology
Personalis Inc
Life Sciences Tools & Services
Pegasystems Inc
Technology
Zentalis Pharmaceuticals Inc
Biotechnology
SIGA Technologies Inc
Pharmaceuticals
R C M Technologies Inc
Professional Services
Imara Inc
Pharmaceuticals
Repligen Corp
Life Sciences Tools & Services
EyePoint Pharmaceuticals Inc
Pharmaceuticals
Nektar Therapeutics
Pharmaceuticals
Qumu Corp
Technology
Insignia Systems Inc
Media
Aptevo Therapeutics Inc
Biotechnology
A
Antares Pharma Inc
Pharmaceuticals
Checkmate Pharmaceuticals Inc
Biotechnology
Sangamo Therapeutics Inc
Biotechnology
Trevena Inc
Biotechnology
Mirum Pharmaceuticals Inc
Biotechnology
Olema Pharmaceuticals Inc
Biotechnology
Myriad Genetics Inc
Biotechnology
Verastem Inc
Biotechnology
Codexis Inc
Life Sciences Tools & Services
OPKO Health Inc
Biotechnology
Harvard Bioscience Inc
Life Sciences Tools & Services
Biogen Inc
Biotechnology
Ionis Pharmaceuticals Inc
Biotechnology
Sotherly Hotels Inc
Real Estate
PPD Inc
Life Sciences Tools & Services
L
LianBio
Biotechnology
Allogene Therapeutics Inc
Biotechnology
OPTIMIZERx Corp
Health Care
Syneos Health Inc
Life Sciences Tools & Services
Synchronoss Technologies Inc
Technology
Harte Hanks Inc
Media
H
Helios and Matheson Analytics Inc
Technology
I
Innovid Corp
Media
Seagen Inc
Biotechnology
F
Fathom Digital Manufacturing Corp
Machinery
SpringWorks Therapeutics Inc
Biotechnology
Suppliers Map

Pfizer Inc has 77 key customers from 11 countries and 6 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

United States of America
50
Cigna Corp
Health Care
Seagen Inc
Biotechnology
Zentalis Pharmaceuticals Inc
Biotechnology
Omeros Corp
Pharmaceuticals
L
LianBio
Biotechnology
Nektar Therapeutics
Pharmaceuticals
P
Puma Biotechnology Inc
Biotechnology
Patterson Companies Inc
Health Care
Regenxbio Inc
Biotechnology
Abbvie Inc
Biotechnology
Henry Schein Inc
Health Care
Homology Medicines Inc
Biotechnology
B
Biodesix Inc
Health Care
SpringWorks Therapeutics Inc
Biotechnology
Mckesson Corp
Health Care
Clovis Oncology Inc
Biotechnology
I
IDEAYA Biosciences Inc
Biotechnology
Oyster Point Pharma Inc
Biotechnology
Ionis Pharmaceuticals Inc
Biotechnology
Biogen Inc
Biotechnology
Verastem Inc
Biotechnology
Imara Inc
Pharmaceuticals
SIGA Technologies Inc
Pharmaceuticals
Mirum Pharmaceuticals Inc
Biotechnology
Coherus BioSciences Inc
Biotechnology
T
Teleflex Inc
Health Care
ICU Medical Inc
Health Care
Myriad Genetics Inc
Biotechnology
Checkmate Pharmaceuticals Inc
Biotechnology
Haemonetics Corp
Health Care
OPKO Health Inc
Biotechnology
Olema Pharmaceuticals Inc
Biotechnology
Trevena Inc
Biotechnology
Arvinas Inc
Pharmaceuticals
Catalyst Biosciences Inc
Biotechnology
Cardinal Health Inc
Health Care
Thermo Fisher Scientific Inc
Life Sciences Tools & Services
Cerevel Therapeutics Holdings Inc
Biotechnology
P
Pyxis Oncology Inc
Biotechnology
Mirati Therapeutics Inc
Biotechnology
Merck & Co Inc
Pharmaceuticals
Cardiff Oncology Inc
Biotechnology
Eli Lilly and Co
Pharmaceuticals
e
eFFECTOR Therapeutics Inc
Biotechnology
Owens & Minor Inc
Health Care
Amerisourcebergen Corp
Health Care
G1 Therapeutics Inc
Biotechnology
Beam Therapeutics Inc
Biotechnology
Zoetis Inc
Pharmaceuticals
Calithera Biosciences Inc
Biotechnology
Customers Map

Ownership

PFE Insider Trading
Buy and sell transactions by insiders

Pfizer Inc insiders have only sold shares in the past 12 months.

During the last 12 months Pfizer Inc insiders have not bought any shares, and sold 7.2M USD worth of shares. The last transaction was made on Feb 6, 2023 by Damico Jennifer B. (SVP & Controller), who sold 228k USD worth of PFE shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
7.2M USD
5
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
No Insider Transactions
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
N/A
N/A
N/A
6 Months
N/A
N/A
N/A
9 Months
7.2M USD
N/A
-7.2M
12 Months
7.2M USD
N/A
-7.2M
Purchases
8
Sales
158
No transactions found
Why is insider trading important?

Shareholder Return

PFE Price
Pfizer Inc

1M 1M
-14%
6M 6M
-11%
1Y 1Y
-16%
3Y 3Y
+33%
5Y 5Y
+55%
Annual Price Range
43.94
52w Low
41.75
52w High
54.48
Price Metrics
Average Annual Return 20.73%
Standard Deviation of Annual Returns 29.38%
Max Drawdown -35%
Shares Statistics
Market Capitalization 247B USD
Shares Outstanding 5 613 310 000
Percentage of Shares Shorted 1.25%

Company Profile

Pfizer Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

247B USD

Dividend Yield

3.74%

Description

Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 79,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The firm offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The firm works across markets to develop wellness, prevention, treatments and cures. The company collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The firm's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.

Contact

NEW YORK
New York City
235 E 42nd St
+12125732323.0
https://www.pfizer.com/

IPO

1944-01-17

Employees

79 000

Officers

Chairman & CEO
Dr. Albert Bourla D.V.M., DVM, Ph.D.
CFO & Exec. VP
Mr. Frank A. D'Amelio
Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical
Dr. Mikael Dolsten M.D., Ph.D.
Exec. VP & Gen. Counsel
Mr. Douglas M. Lankler
Advisor
Mr. John D. Young
Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus.
Ms. Angela Hwang
Show More
Chief Financial Officer & Exec. VP
Mr. David M. Denton
Sr. VP, Controller & Principal Accounting Officer
Ms. Jennifer B. Damico
Exec. VP and Chief Digital & Technology Officer
Ms. Lidia L. Fonseca
Sr. VP & Chief Investor Relations Officer
Mr. Christopher J. Stevo CFA
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one PFE stock?

The intrinsic value of one PFE stock under the Base Case scenario is 53.17 USD.

Is PFE stock undervalued or overvalued?

Compared to the current market price of 43.94 USD, Pfizer Inc is Undervalued by 17%.